Business

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points

articleSpyre Therapeutics, Inc.April 13, 20264/company/spyre-therapeutics-inc/news/spyre-announces-potential-best-in-class-spy001-part-a-induction-results-from-skyline-trial-in-moderate-to-severe-ulcerative-colitis-patients

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

About this update from Spyre Therapeutics, Inc.

[{"type":"text","content":"SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p","length":122,"tagName":"div"}]

More updates from Spyre Therapeutics, Inc.